Expert Consult Series in Multiple Sclerosis
Updates, Clinical Scenarios, and Future Directions
Infectious complications of multiple sclerosis therapies: implications for screening, prophylaxis, and management.
Epstein DJ, Dunn J, Deresinski S. Open Forum Infect Dis. 2018;5(8):ofy174.
Disease-modifying treatments for early and advanced multiple sclerosis: a new treatment paradigm.
Giovannoni G. Curr Opin Neurol. 2018;31(3):233-243.
Ofatumumab versus teriflunomide in multiple sclerosis.
Hauser SL, Bar-Or A, Cohen JA, et al. N Engl J Med. 2020;383(6):546-557.
Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis.
Hauser SL, Bar-Or A, Comi G, et al. N Engl J Med. 2017;376(3):221-234.
Treatment of multiple sclerosis: a review.
Hauser SL, Cree BAC. Am J Med. 2020;133(12):1380-1390.e2.
The role of infections in multiple sclerosis.
Marrodan M, Alessandro L, Farez MF, Correale J. Mult Scler. 2019;25(7):891-901.
The risk of infection in patients with multiple sclerosis treated with disease-modifying therapies: a Delphi consensus statement.
Moiola L, Barcella V, Benatti S, et al. Mult Scler. 2021;27(3):331-346.
Infection mitigation strategies for multiple sclerosis patients on oral and monoclonal disease-modifying therapies.
Smith TE, Kister I. Curr Neurol Neurosci Rep. 2021;21(7):36.
The contribution of enhancing lesions in monitoring multiple sclerosis treatment: is gadolinium always necessary?
Tsantes E, Curti E, Ganazzoli C, et al. J Neurol. 2020;267(9):2642-2647.
Clinical Practice Guidelines
Practice guideline update summary: vaccine-preventable infections and immunization in multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology.
Farez MF, Correale J, Armstrong MJ, et al. Neurology. 2019;93(13):584-594.
COVID-19 vaccine guidance for people living with MS.
National Multiple Sclerosis Society.
Practice guideline recommendations summary: disease-modifying therapies for adults with multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology.
Rae-Grant A, Day GS, Marrie RA, et al. Neurology. 2018;90(17):777-788.
Patient and Caregiver Resources
Consortium of Multiple Sclerosis Centers
Multiple Sclerosis Association of America
National Multiple Sclerosis Society
Viral infection, DMTs, and MS
Activity 1
| Faculty: | Patricia K. Coyle, MD and Stephen C. Krieger, MD |
| Release: | 12/20/2021 |
| Expiration: | 12/20/2022 |
Switching DMTs
Activity 2
| Faculty: | Anne H. Cross, MD and Augusto Miravalle, MD |
| Release: | 01/18/2022 |
| Expiration: | 01/18/2023 |
Which S1P receptor modulator is right for your patient?
Activity 3
| Faculty: | Robert Bermel, MD and Ilana B. Katz Sand, MD |
| Release: | 02/15/2022 |
| Expiration: | 02/15/2023 |
An emerging therapeutic class in MS
Activity 4
| Faculty: | Carrie Hersh, DO, MSc and Stephen C. Krieger, MD |
| Release: | 03/18/2022 |
| Expiration: | 03/18/2023 |
